5 news items
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
ARVN
23 May 24
abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCEĀ®)
ARVN
PFE
16 May 24
cohort evaluating vepdegestrant, an investigational oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
ARVN
9 May 24
Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany. Vepdegestrant is a novel investigational PROTAC® estrogen receptor
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
ARVN
NVS
7 May 24
+/HER2-) locally advanced or metastatic breast cancer.Received U.S. Food and Drug Administration Fast Track designation for the investigation
Arvinas to Present at Upcoming Investor Conferences
ARVN
2 May 24
investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast
- Prev
- 1
- Next